Research Topics
Genomes and Genes | Seth P LernerSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomyKazumasa Matsumoto
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
J Urol 170:2248-52. 2003..These patients may benefit from more extensive lymph node dissection and/or combined modality treatment regimens...
Treatment of high-risk, non-muscle-invasive bladder cancerSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Nat Clin Pract Urol 3:398-9. 2006
Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancerAlvin C Goh
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030 2706, USA
Urology 72:133-7. 2008..The purpose of this study was to examine the application of OCT in augmenting the diagnosis and staging of bladder lesions...
The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinomaSeth P Lerner
Scott Department of Urology, Dan Duncan Cancer Center, Translational and Molecular Medicine Program, Baylor College of Medicine, 6620 Main Suite 1325, Houston, TX 77030, USA
Curr Treat Options Oncol 10:267-74. 2009....
Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancerSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
Urol Oncol 26:481-5. 2008..Further studies are necessary to establish the role of neoadjuvant and adjuvant therapy for patient with prostatic stroma invasion...
Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinomaSeth P Lerner
Baylor College of Medicine, Scott Department of Urology, Dan Duncan Cancer Center, Department of Pathology, Methodist Hospital, Houston, Texas 77030, USA
Curr Opin Urol 18:508-12. 2008..To review the current fund of knowledge about prostatic transitional cell carcinoma and the implications for diagnostic and management strategies particularly as they relate to radical cystectomy...
BCAN Think Tank session 3: Prevention of bladder cancerSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Urol Oncol 28:338-42. 2010..These markers, combined with histories of environmental exposure to bladder carcinogens, may provide a tool to identify patients who will benefit from primary prevention...
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancerSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Urol Oncol 27:155-9. 2009..Among all patients randomized to maintenance treatment, we also wanted to identify combinations of baseline covariates in order to define prognostic groups for subsequent worsening-free survival...
Bladder cancer clinical trialsSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Urol Oncol 23:275-9. 2005..The present article reviews this important area of clinical trials research...
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancerSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
J Urol 177:1727-31. 2007..We explored a large prospective data set from the SWOG 8507 randomized trial of maintenance bacillus Calmette-Guerin to better understand this risk and specifically to assess the impact of timing of recurrence on survival...
The use and abuse of data: nomograms and talking to patients about clinical medicineSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Urol Oncol 25:333-7. 2007..To review the development of nomograms and consortia efforts applying these tools to model outcome predictions associated with radical cystectomy...
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomyGuru Sonpavde
Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
BJU Int 108:687-92. 2011..To stratify risk of pathological (p) T2N0 urothelial carcinoma of the bladder after radical cystectomy (RC) based on pathological factors to facilitate the development of adjuvant therapy trials for high-risk patients...
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladderShahrokh F Shariat
Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas 77030, USA
Urology 61:1053-8. 2003..We tested the hypothesis that preoperative plasma levels of uPA and its specific receptor, uPAR, would predict cancer stage and prognosis in patients with transitional cell carcinoma of the bladder...
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancerGuru Sonpavde
Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
J Urol 185:456-61. 2011..We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival...
Case-control analysis of dietary folate and risk of bladder cancerMatthew B Schabath
The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Nutr Cancer 53:144-51. 2005..These data may have important implications for cancer prevention; however, large, hypothesis-driven, population-based clinical trials will be required to confirm these findings...
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancerShahrokh F Shariat
Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
J Clin Oncol 22:1014-24. 2004....
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapyGuru Sonpavde
Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
Cancer 115:4104-9. 2009....
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signalingJonathan M Levitt
Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
Mol Cancer Ther 9:1128-35. 2010..Further clinical development might be warranted in selected human subjects...
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancerAnita L Sabichi
Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
Clin Cancer Res 14:224-9. 2008..The study aims to evaluate the efficacy and toxicity of fenretinide in preventing tumor recurrence in patients with transitional cell carcinoma (TCC) of the bladder...
The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancerShahrokh F Shariat
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
J Urol 170:2244-7. 2003..An approach using multiple biomarkers may improve the diagnostic accuracy of voided urinary diagnostic tests...
Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significanceSteven S Shen
Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
Hum Pathol 37:726-34. 2006..In summary, presence of prostatic TCC involvement and levels of involvement are significant prognostic factors in patients with bladder cancer...
Combining surgery and chemotherapy for invasive bladder cancer: current and future directionsGilad E Amiel
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Expert Rev Anticancer Ther 6:281-91. 2006..Prospective validation of molecular markers and evaluation of novel therapeutic agents, alone or in combination with established cytotoxic agents, provide hope of better outcomes for bladder cancer patients...
Neoadjuvant chemotherapy for bladder cancerGuru Sonpavde
Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Webster 77598, USA
Oncology (Williston Park) 21:1673-81; discussion 1686-8, 1691, 1694. 2007..Patients who are either unfit for or refuse radical cystectomy may benefit from neoadjuvant chemotherapy with or without radiation to enable bladder preservation...
Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladderShahrokh F Shariat
Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
Urology 61:1140-5. 2003..To determine whether p53 and p21 expression in bladder carcinoma in situ (CIS) with or without papillary disease can predict disease recurrence, progression, and survival...
Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancerShahrokh F Shariat
Baylor Prostate Center, Scott Department of Urology, Baylor College of Medicine, and Methodist Hospital, Houston, Texas 77030-2706, USA
Urology 61:359-64. 2003..In contrast, a lower preoperative plasma level of IGFBP-3 was associated with lymph node metastasis and poorer clinical outcome after radical cystectomy when adjusted for IGF-I level...
Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabineWeiguo Jian
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
Mol Cancer Ther 8:1772-8. 2009..IHC showed reduced Ki-67 and CD31 and increased cleaved caspase-3 with combination therapy compared with controls. Enzastaurin showed preclinical antitumor activity against human TCC and enhanced the activity of gemcitabine...
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladderRobert S Svatek
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Clin Cancer Res 16:4461-7. 2010..Here we address the value of adjuvant chemotherapy in patients undergoing radical cystectomy for UCB in an off-protocol routine clinical setting...
Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladderSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Urol Oncol 30:285-9. 2012..To understand the additional benefits of HAL compared with conventional cystoscopy at the patient level and to explore relationships of urine cytology and CIS...
High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer riskMeng Chen
Department of Epidemiology and Urology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Carcinogenesis 28:2160-5. 2007..The contributions of these polymorphisms may jointly affect bladder cancer risk through gene-gene and gene-smoking interactions...
Polymorphisms in XPD exons 10 and 23 and bladder cancer riskMatthew B Schabath
Department of Epidemiology, University of Texas M D Anderson Cancer Center, Unit 189, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Epidemiol Biomarkers Prev 14:878-84. 2005....
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical modelGuru Sonpavde
Texas Oncology, P A and U S Oncology Research, Houston, TX 77030, USA
Urol Oncol 27:391-9. 2009..Angiogenesis and VEGF expression correlate with poor outcomes in human urothelial carcinoma. We designed a preclinical study to examine the efficacy of sunitinib alone and in combination with cisplatin against human urothelial carcinoma...
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissueSteven S Shen
Department of Pathology, The Methodist Hospital and Baylor College of Medicine, Houston, Texas 77030, USA
Cancer 106:2610-6. 2006..In a previous study the selective ER modulator raloxifene was shown to induce apoptosis in an ERbeta-positive bladder cancer cell line. However, the expression of ERbeta in human bladder cancer has not been thoroughly investigated...
Racial/ethnic differences in upper-tract urothelial cancerG M Monawar Hosain
Houston VA Health Services Research and Development Center of Excellence, Houston, Texas, USA
Ethn Dis 22:295-301. 2012..Our study examined the racial/ethnic differences in patients diagnosed with incident UTUC...
Prostatic transitional cell carcinoma: pathologic features and clinical managementSteven S Shen
Department of Pathology, The Methodist Hospital and Weill Medical College of Cornell University, 6565 Fannin Street, Houston, TX 77030, USA
Expert Rev Anticancer Ther 7:1155-62. 2007..A rational approach for management of pTCC in patients with bladder cancer will be proposed on the basis of our experience and our review of literature...
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohortSalahaldin A Tahir
Scott Department of Urology and Department of Pathology, Baylor College of Medicine, Houston, Texas, USA
Clin Cancer Res 12:4872-5. 2006..In the subset of patients with serum PSA of >/=10 ng/mL, the combination of serum cav-1 and biopsy Gleason score has the capacity to predict time to biochemical recurrence...
Strategies to prevent progression of high-risk bladder cancer at initial diagnosisJa H Ku
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
Curr Opin Urol 22:405-14. 2012..As high-risk nonmuscle invasive bladder cancer (NMIBC) has a high propensity to recur and progress, the primary therapeutic goal in patients with high-risk NMIBC is the prevention or delay of disease recurrence and progression...
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancerAnita L Sabichi
Department of Medicine, Division of Hematology Oncology, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Prev Res (Phila) 4:1580-9. 2011..Our clinical trial results do not show a clinical benefit for celecoxib in preventing NMIBC recurrence but further investigation of COX-2 inhibitors in this setting is warranted...
Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adultMohammadbagher Ziari
Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA
J Clin Oncol 23:4459-60. 2005
Novel agents for muscle-invasive and advanced urothelial cancerGuru Sonpavde
US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
BJU Int 101:937-43. 2008..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
Stage specific lymph node metastasis mapping in radical cystectomy specimensAmnon Vazina
Scott Department of Urology, Baylor College of Medicine, Methodist and Saint Luke's Episcopal Hospitals, Houston, Texas 77030, USA
J Urol 171:1830-4. 2004..Extensive LN dissection is essential for the complete removal of disease and accurate staging...
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladderShahrokh F Shariat
Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
J Urol 169:938-42. 2003..We could not substantiate a role for COX-2 immunohistochemistry for the staging and prognosis of carcinoma in situ and/or stage T1 transitional cell carcinoma...
Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancerKazumasa Matsumoto
Scott Department of Urology, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
Urology 66:441-6. 2005..The association of CAR with E-cadherin and p53 suggests a potential role for CAR in the regulation of urothelium integrity and the cell cycle...
Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancerShahrokh F Shariat
Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
J Urol 171:626-30. 2004..Urine detection of survivin is an accurate diagnostic test for bladder cancer that retains its efficiency regardless of cancer stage and grade...
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancerVitaly Margulis
Department of Urologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
J Natl Cancer Inst 101:114-9. 2009....
Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancerArup Chakraborty
Department of Pediatrics, Section of Leukocyte Biology, Baylor College of Medicine, Houston, Texas 77030, USA
Urology 63:177-83. 2004..In neutrophils, G-CSF acts through its receptor to enhance adhesion and migration. A significant fraction of bladder carcinoma has been reported to express both G-CSF and G-CSFR...
Dietary carotenoids and genetic instability modify bladder cancer riskMatthew B Schabath
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
J Nutr 134:3362-9. 2004..18; 95% CI, 1.13-4.22). This study provides evidence of a preventive role for carotenoids in bladder cancer, and these data may have important implications for cancer prevention, especially for individuals susceptible to DNA damage...
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinomaRoberto Casella
the Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Cancer 95:2494-9. 2002..CONCLUSIONS: The current findings suggest that urinary levels of uPA, but not uPAR, are related to the risk of bladder carcinoma. The study confirmed the central role of urinary cytology in the noninvasive diagnosis of bladder carcinoma...
Centrosomal abnormality is common in and a potential biomarker for bladder cancerFeng Jiang
Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Int J Cancer 106:661-5. 2003..Centrosomal abnormalities appear to be intrinsic to aneuploidy and tumorigenesis and may be potential markers for early detection of bladder cancer...
Bladder cancer screening program for a petrochemical cohort with potential exposure to beta-napthylamineSarah A Felknor
University of Texas Health Science Center at Houston, School of Public Health, Southwest Center for Occupational and Environmental Health, Houston, TX, USA
J Occup Environ Med 45:289-94. 2003..Original personnel records are often incomplete, making cohort identification important. Personal contact and follow-up are key elements of successful recruitment and retention...
Bladder cancer detection, treatment and outcomes: opportunities and challengesDavid M Latini
Scott Department of Urology and Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
Urology 75:334-9. 2010..Increasing national attention to BlCa is likely to improve disease burden and patient quality of life...
Innovations in radical cystectomy and pelvic lymph node dissectionLambros Stamatakis
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Semin Oncol 39:573-82. 2012..Anatomic pelvic and iliac lymphadenectomy is crucial for precise pathologic staging and may improve patient survival by removing micrometastatic disease...
Alternatives to cytology in the management of non-muscle invasive bladder cancerGilad E Amiel
Baylor College of Medicine, 6560 Fannin Street, Suite 2100, Houston, TX 77030, USA
Curr Treat Options Oncol 5:377-89. 2004....
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group StudyAnita L Sabichi
University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas, USA
Clin Cancer Res 12:2178-84. 2006..Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue...
Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancerBen Andrews
Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
J Urol 167:1475-81. 2002..Levels of IL-6 and IL-6sR were associated with cancer stage and metastases, and were strong independent predictors of disease recurrence and disease specific survival...
Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitroC T F Freund
Scott Department of Urology, Baylor College of Medicine, and The Methodist Hospital, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
Urol Oncol 21:197-205. 2003..Additional studies exploring the role of methotrexate in enhancing the tk-GCV system are required. Investigation of other, potentially more synergistic chemotherapeutic agents in combination with tk-GCV is warranted...
Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladderMohammadbagher Ziari
Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA
J Clin Oncol 23:4458-9. 2005
Application of new technology in bladder cancer diagnosis and treatmentAlvin C Goh
Scott Department of Urology, Baylor College of Medicine, 6620 Main Street, Suite 1325, Houston, TX 77030, USA
World J Urol 27:301-7. 2009..We aim to provide an overview of the strengths and weaknesses of these imaging modalities and examine their potential impact on the diagnosis and management of bladder cancer...
Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer riskHua Zhao
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
J Urol 169:714-7. 2003..Because insulin-like growth factors (IGFs) and their binding proteins have been implicated in the development of prostate, breast, colon and lung cancer, we examined the role of IGF-1 and IGF binding protein-3 levels in bladder cancer risk...
Raloxifene Inhibits Growth of RT4 Urothelial Carcinoma Cells via Estrogen Receptor-Dependent Induction of Apoptosis and Inhibition of ProliferationKristi L Hoffman
Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA
Horm Cancer 4:24-35. 2013..These results indicate that antiestrogens may be useful therapeutics in the treatment of bladder cancer by targeting ER and inhibiting growth via multiple mechanisms...
Urine survivin as a diagnostic biomarker for bladder cancer: a systematic reviewJa Hyeon Ku
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
BJU Int 110:630-6. 2012..The clinical utility of urine survivin as a bladder tumour marker identified in the present study remains to be elucidated...
Advances in diagnosis and therapy of transitional cell carcinoma of the bladderSeth P Lerner
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
Urol Oncol 24:324-5. 2006
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladderCraig G Rogers
Bladder Cancer Research Consortium, James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287-2101, USA
J Urol 175:2048-53; discussion 2053. 2006..Patients with bladder TCC and SCC share similar stage specific clinical outcomes...
Cancer specific outcomes in patients with pT0 disease following radical cystectomyGanesh S Palapattu
James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA
J Urol 175:1645-9; discussion 1649. 2006..We assessed clinical outcomes in patients found to have no evidence of disease, ie pT0, in the cystectomy specimen following radical cystectomy for transitional cell carcinoma...
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomyYair Lotan
Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9110, USA
J Clin Oncol 23:6533-9. 2005..We hypothesized that bladder cancer patients with associated lymphovascular invasion (LVI) are at increased risk of occult metastases...
Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survivalPatrick J Bastian
The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
BJU Int 101:450-4. 2008....
Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladderShahrokh F Shariat
Department of Urology, University of Texas Southwestern Medical School 5323 Harry Hines Blvd, Dallas, Texas 75390 9110, USA
Eur Urol 48:69-76. 2005..To test the hypothesis that elevated urinary levels of soluble E-cadherin (sE-cadherin) would aid in the detection of transitional cell carcinoma (TCC) of the urinary bladder...
Perioperative chemotherapy in locally advanced bladder cancerWalter M Stadler
Department of Medicine, Section of Hematology/Oncology and Urology, University of Chicago, Chicago, IL 60637, USA
Lancet 361:1922-3. 2003
Neoadjuvant chemotherapy preceding cystectomy for bladder cancerGuru Sonpavde
Texas Oncology, P A and US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA
Expert Opin Pharmacother 9:1885-93. 2008..Occult micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced, muscle-invasive transitional cell carcinoma of the bladder...
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomyShahrokh F Shariat
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
Eur Urol 51:137-49; discussion 149-51. 2007..We compared clinical and pathologic staging in a large, contemporary, consecutive series of patients who were treated with radical cystectomy and pelvic lymphadenectomy, and determined the effect of stage discrepancy on outcomes...
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcomeMatthew E Nielsen
The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
BJU Int 100:1015-20. 2007....
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomyShahrokh F Shariat
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
Cancer 112:315-25. 2008....
Nomograms provide improved accuracy for predicting survival after radical cystectomyShahrokh F Shariat
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, and The Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
Clin Cancer Res 12:6663-76. 2006....
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomyMatthew E Nielsen
The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA
Eur Urol 51:699-706; discussion 706-8. 2007..The aim of our study was to assess the impact of patient age on pathological characteristics and recurrence-free and disease-specific survival following RC...
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research ConsortiumShahrokh F Shariat
Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
J Urol 176:2414-22; discussion 2422. 2006..We present the characteristics and outcomes of a large, contemporary, consecutive series of patients treated with radical cystectomy and pelvic lymphadenectomy for transitional cell carcinoma of the bladder...
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomyAmit Gupta
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
Urology 71:302-7. 2008..The aim of the present study was to assess the pathologic features and clinical outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma (UCBC) treated with radical cystectomy...
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control studyJochen Walz
Cancer Prgonosis and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
BJU Int 101:1356-61. 2008....
Precystectomy nomogram for prediction of advanced bladder cancer stagePierre I Karakiewicz
Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
Eur Urol 50:1254-60; discussion 1261-2. 2006..To evaluate precystectomy prediction of pT and pN stages at cystectomy...
Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladderPierre I Karakiewicz
Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
J Urol 176:1354-61; discussion 1361-2. 2006....
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomyShahrokh F Shariat
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
Eur Urol 51:152-60. 2007..The aim of this study was to assess whether presence of concomitant CIS has a detrimental effect on cancer control after radical cystectomy...
Molecular markers in bladder cancerShahrokh F Shariat
Department of Urology, UT Southwestern Medical Center, Dallas, Texas 75390 9110, USA
Curr Opin Urol 18:1-8. 2008..Bladder cancer is a diverse disease whose molecular phenotypes are being elucidated. In this review, we summarize currently known molecular pathways and associated markers in bladder cancer...
Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomyShahrokh F Shariat
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9110, USA
Urology 68:538-42. 2006..001). CONCLUSIONS: Disease control seemed durable for patients with pathologic CIS only at radical cystectomy in the absence of metastases to the lymph nodes, even in the case of failure after intravesical therapy...
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1Isaac Yi Kim
Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland, USA
Cancer Res 64:7355-60. 2004....
Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinomaGuru Sonpavde
U S Oncology Research, Webster, Texas, USA
Urology 69:1221-6. 2007..To evaluate estrogen receptors as a therapeutic target for human bladder cancer...
Chemoprevention of bladder cancerDragan J Golijanin
Urology Department, University of Rochester Medical Center, 601 Elmwood Avenue, P.O. Box 656, Rochester, NY 14642, USA
World J Urol 24:445-72. 2006
Editorial comment on: Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible lightSeth P Lerner
Eur Urol 52:1708-9. 2007
